🇺🇸 Yttrium-90 ibritumomab tiuxetan in United States

87 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 87

Most-reported reactions

1. Myelodysplastic Syndrome — 17 reports (19.54%)
2. Neutropenia — 14 reports (16.09%)
3. Acute Myeloid Leukaemia — 12 reports (13.79%)
4. Thrombocytopenia — 12 reports (13.79%)
5. Anaemia — 8 reports (9.2%)
6. Febrile Neutropenia — 8 reports (9.2%)
7. Infection — 5 reports (5.75%)
8. Diarrhoea — 4 reports (4.6%)
9. Pneumonia — 4 reports (4.6%)
10. Colon Cancer — 3 reports (3.45%)

Source database →

Frequently asked questions

Is Yttrium-90 ibritumomab tiuxetan approved in United States?

Yttrium-90 ibritumomab tiuxetan does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Yttrium-90 ibritumomab tiuxetan in United States?

SWOG Cancer Research Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.